Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eissing

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Eye (London, England)|May 20, 2026
Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologistSamia Ezzine, Richard Gale, Clare Bailey, et al.
Clinical Pharmacokinetics|November 13, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event AnalysisPaul van den Berg, Martijn Ruppert, Emir Mesic, et al.
Journal of Clinical Pharmacology|June 29, 2021
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in ChildrenIbrahim Ince, André Dallmann, Sebastian Frechen, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 1, 2026
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug ProductsSébastien Bihorel, Joannellyn Chiu, Jason Chittenden, et al.
Diabetes, Obesity & Metabolism|December 1, 2023
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKDThomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, et al.
Eye (London, England)|January 10, 2024
Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 studyAndreas Stahl, Noriyuki Azuma, Wei-Chi Wu, et al.
Frontiers in Physiology|April 13, 2011
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networksThomas Eissing, Lars Kuepfer, Corina Becker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 8, 2023
Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record DatabaseCaroline A Gluck, Christopher B Forrest, Amy Goodwin Davies, et al.
Lancet (London, England)|June 5, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)Brendon L Neuen, Hiddo J L Heerspink, Vlado Perkovic, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Eye (London, England)|May 20, 2026
Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologistSamia Ezzine, Richard Gale, Clare Bailey, et al.
Clinical Pharmacokinetics|November 13, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event AnalysisPaul van den Berg, Martijn Ruppert, Emir Mesic, et al.
Journal of Clinical Pharmacology|June 29, 2021
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in ChildrenIbrahim Ince, André Dallmann, Sebastian Frechen, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 1, 2026
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug ProductsSébastien Bihorel, Joannellyn Chiu, Jason Chittenden, et al.
Diabetes, Obesity & Metabolism|December 1, 2023
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKDThomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, et al.
Eye (London, England)|January 10, 2024
Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 studyAndreas Stahl, Noriyuki Azuma, Wei-Chi Wu, et al.
Frontiers in Physiology|April 13, 2011
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networksThomas Eissing, Lars Kuepfer, Corina Becker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 8, 2023
Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record DatabaseCaroline A Gluck, Christopher B Forrest, Amy Goodwin Davies, et al.
Lancet (London, England)|June 5, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)Brendon L Neuen, Hiddo J L Heerspink, Vlado Perkovic, et al.
Pageof 5